FGL(S) is a synthetic peptide derived from the neural cell adhesion molecule (NCAM) that directly activates the fibroblast growth factor receptor (FGFR). It promotes neurite outgrowth, neuronal survival, and synaptic plasticity in preclinical models.
Category: Neuroprotection / Research. Evidence rating: D (animal/preclinical only).
Clinical status: Research-only
FGL(S) activates FGFR independent of FGF ligands, promoting neurite outgrowth and neuronal survival. It enhances synaptic plasticity and provides anti-apoptotic signaling in neurons via downstream MAPK/ERK and PI3K/Akt pathways.
Safety considerations: No human safety data; FGFR activation raises theoretical oncogenicity concerns.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | synthetic |
|---|---|
| Anti-doping status | not-listed |
There is no human safety data. FGFR activation is associated with cell growth pathways that have oncogenic potential. This is entirely a research compound.
FGL(S) is a synthetic peptide derived from the neural cell adhesion molecule (NCAM) that directly activates the fibroblast growth factor receptor (FGFR). It promotes neurite outgrowth, neuronal survival, and synaptic plasticity in preclinical models.
On the PeptideAtlas A–F scale, FGL(S) is rated D (Preclinical Only). Mostly animal or preclinical evidence
Research-only
FGL(S) activates FGFR independent of FGF ligands, promoting neurite outgrowth and neuronal survival. It enhances synaptic plasticity and provides anti-apoptotic signaling in neurons via downstream MAPK/ERK and PI3K/Akt pathways.